{"entity":{"id":"nct07510828","kind":"trial","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of EB-PT-CAR-NK-S in advanced solid tumours, run by Beijing Biotech, now recruiting.","summary":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07510828 by Beijing Biotech, with 60 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy and Cytokine support.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07510828","url":"https://clinicaltrials.gov/study/NCT07510828"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07510828","phase":"1/2","setting":"A Phase 1/2 Biomarker-Guided Platform Study of Allogeneic Donor-Derived Single-Target or Dual-Target CAR-NK Cell Therapy Selected by Tumor Antigen Profiling (Liquid Biopsy and/or Tissue Biopsy) in Participants With Advanced Solid Tumors","sponsor":"Beijing Biotech","enrolled":60,"outcomes":[]},"route":"/trials/nct07510828/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}